Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mortality in prostatic carcinoma.

D A Kuban1, A M el-Mahdi, P F Schellhammer

  • 1Department of Radiation Oncology and Biophysics, Eastern Virginia Medical School, Norfolk.

Urology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.

Prostate cancer and prostatic diseases·2017
Same author

Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients.

Prostate cancer and prostatic diseases·2013
Same author

Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

What is the available evidence to support immediate adjuvant intravesical chemotherapy after transurethral resection of superficial transitional cell carcinoma of the bladder?

Urologic oncology·2011
Same author

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction.

Urologic oncology·2011
Same author

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

Urologic oncology·2011
Same journal

"Editorial Comment on "Vaginal Estrogen Prescription is Associated with Reduced Rates of Serious Adverse Outcomes in Women of All Age Groups With Recurrent Urinary Tract Infection: An Epic Cosmos Database Analysis".

Urology·2026
Same journal

The True Oral History of Buccal Mucosal Grafts for Male Urethral Stricture Repair.

Urology·2026
Same journal

Preventing Postpartum Pelvic Floor Dysfunction: Clinical Evidence and Policy Gaps in U.S. Coverage of Pelvic Floor Muscle Therapy.

Urology·2026
Same journal

Editorial Comment on "Through the Eyes of the Applicant: A Qualitative Study of the Urology Residency Match".

Urology·2026
Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026
Same journal

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026
See all related articles

Definitive radiation therapy for prostate cancer shows promising long-term results. Over half of patients treated between 1975-1979 were disease-free after a median of 45 months, with outcomes linked to tumor stage and differentiation.

Area of Science:

  • Urology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Prostate cancer treatment outcomes require long-term evaluation.
  • Assessing the efficacy of definitive radiation therapy is crucial for patient management.

Purpose of the Study:

  • To evaluate the long-term survival and disease control rates in patients with adenocarcinoma of the prostate treated with definitive irradiation.
  • To identify prognostic factors associated with disease-free survival after radiation therapy.

Main Methods:

  • Retrospective analysis of 147 patients with biopsy-proven prostate adenocarcinoma treated definitively with irradiation from December 1975 to March 1979.
  • Follow-up for a minimum of seven years or until death, with assessment of survival, disease status, and recurrence patterns.

Related Experiment Videos

Main Results:

  • 76 patients (52%) are alive, with 62 showing no evidence of disease.
  • 61% of all patients had no further evidence of prostate carcinoma post-irradiation.
  • Disease control was significantly associated with tumor stage, histologic differentiation, pelvic lymph node status, and rebiopsy results.

Conclusions:

  • Definitive irradiation offers durable disease control for prostate cancer.
  • Tumor stage, differentiation, and nodal status are critical predictors of treatment success.
  • Distant metastasis was the predominant pattern of failure in deceased patients.